Adris, Ericsson Nikola Tesla push higher Croatian share indices
Sales of new dwellings in Bosnia's Federation up 1.2% in 2023
Ljubljana share indices decline, Cinkarna Celje paces losers
Sales of new dwellings in Bosnia up 26.3% y/y in Q4
Romanian stock indices turn red, Electrica leads decliners
Dec 05, 2023 15:07 EEST
December 5 (SeeNews) - Serbian drug maker Hemofarm, a unit of Germany's Stada, said it plans to invest 100 million euro ($108.2 million) to secure a reliable supply network.
Numerous projects that are in the pipeline over the next few years will positioning Hemofarm among mega-production hubs, even on an international scale, Hemofarm’s general director Ronald Zeliger said in a press release on Monday.
In 2023, Hemofarm anticipates double-digit growth, fueled by the introduction of new medications for multiple sclerosis and a novel flu virus treatment.
Stada, which took over Hemofarm in 2006, has so far invested more than 450 million euro in the modernisation of equipment and production facilities in Serbia's eastern town of Vrsac.
Hemofarm’s factories are located in Serbia, Montenegro and Bosnia and Herzegovina.
$ = 0.9242 euro
You have run out of free articles this month.
Sign up in for
and get ten (10) free articles per month or sign up for
and get unlimited access.
Browse our free newsletter options